Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
Authors
Keywords
Multiple Sclerosis, Alemtuzumab, Glatiramer Acetate, Magnetisation Transfer Ratio, Immune Thrombocytopenia
Journal
DRUGS
Volume 74, Issue 4, Pages 489-504
Publisher
Springer Nature
Online
2014-03-06
DOI
10.1007/s40265-014-0195-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Outlook for Alemtuzumab in Multiple Sclerosis
- (2013) Thomas Williams et al. BIODRUGS
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- (2013) J. L. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alemtuzumab Treatment of Multiple Sclerosis
- (2013) Alasdair Coles SEMINARS IN NEUROLOGY
- Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
- (2013) William Brown et al. Drug Design Development and Therapy
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab
- (2012) T. Button et al. Multiple Sclerosis Journal
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
- (2010) Joanne L. Jones et al. BRAIN
- Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab
- (2010) Joanne Jones et al. CLINICAL IMMUNOLOGY
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain
- (2009) E. Ramil et al. Multiple Sclerosis Journal
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More